We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · November 12, 2019

Improved Survival After Adding SBRT to TKI in mRCC

American Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

American Journal of Clinical Oncology
Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors
Am. J. Clin. Oncol 2019 Oct 22;[EPub Ahead of Print], L He, Y Liu, H Han, Z Liu, S Huang, W Cao, B Liu, Z Qin, S Guo, Z Zhang, M Lin, X Jiang, C Lin, Y Li, K Yao, P Dong, F Zhou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading